The MaxCmin Trial
The MaxCmin trial will evaluate the safety and efficacy of indinavir/ritonavir (800/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infected patients. It is an open-label, multi-centre trial including 317 patients from Europe as well as North- and South America. Randomization decided the treatment assigned to the individual patient.
The first patient was randomized on 5 September 2000. Recruitment was closed on 20 March 2001 with 317 patients randomised.
The interim analysis was presented at EACS Conference, Athens, October 2001.
Presentation of final results on toxicity was presented at the XIV International AIDS Conference in Barcelona 2002.
Final analysis was presented at the Sixth International Congress on Drug Therapy in HIV Infection in Glasgow 2002.
Data from the pharmacokinetic substudy and from the substudy on clinical lipodystrophy and retinoid syndrome were presented at the 9th EACS, Warsaw, 2003.
Updated: 20 Dec 2005